MYGN
- Myriad Genetics, Inc.
()
Overview
Company Summary
Myriad Genetics, Inc. is a biotechnology company that specializes in molecular diagnostics and personalized medicine. The company focuses on developing and marketing innovative molecular diagnostic tests that analyze genes, proteins, and other biomarkers to provide information crucial for assessing a patient's risk of developing diseases, such as cancer and predictive testing for inherited disorders.
Myriad Genetics primarily operates in three main segments: Diagnostic Testing, Pharmaceutical, and Research. In the Diagnostic Testing segment, the company offers several proprietary tests, including Hereditary Cancer Testing, Prenatal Testing, and Companion Diagnostics. These tests assist healthcare providers in assessing the risk of developing various cancers and genetic conditions and enable them to adopt targeted treatment approaches.
In the Pharmaceutical segment, Myriad Genetics is involved in the discovery and development of therapeutics and companion diagnostics, focusing on oncology and reproductive health. The company aims to identify and develop novel drugs to address unmet medical needs, leveraging its expertise in genetic research and molecular diagnostics.
Under the Research segment, Myriad Genetics collaborates with academic institutions, pharmaceutical companies, and other research organizations to support genetic research efforts. The company's vast genetic database and its comprehensive understanding of the human genome enable it to contribute valuable insights into the genetic basis of diseases and aid in the development of new therapies.
Overall, Myriad Genetics is at the forefront of molecular diagnostics, offering advanced genetic testing solutions that empower healthcare providers to make more informed treatment decisions. Through their dedication to personalized medicine and ongoing research efforts, the company aims to continue improving patient outcomes and revolutionizing the field of genetic testing and therapeutics.